Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0	28.31	2.88	1.49
Revenue Growth (YoY)	-	-	883.06%	93.68%	-63.09%
Cost of Revenue	0	0	0.43	1.19	0.64
Gross Profit	0	0	27.88	1.69	0.85
Selling, General & Admin	11.9	5.63	18.49	17.99	9.6
Research & Development	23.85	18.1	48.7	38.98	29.84
Operating Expenses	35.75	23.73	67.19	56.96	39.44
Operating Income	-35.75	-23.73	-39.31	-55.27	-38.59
Interest Expense / Income	1.06	3.6	1.85	8.85	-0.27
Other Expense / Income	-1.61	0.88	13.42	15.99	2.33
Pretax Income	-35.2	-28.21	-54.57	-80.11	-40.66
Net Income	-35.2	-28.21	-54.57	-80.11	-40.66
Shares Outstanding (Basic)	5	0	3	1	1
Shares Outstanding (Diluted)	5	0	3	1	1
Shares Change	1500.08%	-88.81%	91.33%	2.26%	49.03%
EPS (Basic)	-6.96	-89.27	-19.30	-54.30	-28.20
EPS (Diluted)	-6.96	-89.27	-19.30	-54.30	-28.20
Free Cash Flow	-32.73	-22.83	-53.03	-22.93	-24.83
Free Cash Flow Per Share	-6.47	-72.26	-18.77	-15.53	-17.20
Gross Margin	-	-	98.47%	58.68%	56.96%
Operating Margin	-	-	-138.84%	-1919.20%	-2595.23%
Profit Margin	-	-	-192.76%	-2781.49%	-2734.23%
Free Cash Flow Margin	-	-	-187.29%	-796.15%	-1669.87%
EBITDA	-32.97	-23.55	-51.93	-70.63	-40.43
EBITDA Margin	-	-	-183.40%	-2452.53%	-2718.70%
Depreciation & Amortization	1.17	1.06	0.8	0.63	0.5
EBIT	-34.14	-24.61	-52.73	-71.26	-40.92
EBIT Margin	-	-	-186.23%	-2474.34%	-2752.05%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).